Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 3/20 | 0.37 |
| ▸ | METAP1 | P53582 | 3/20 | 0.37 |
| ▸ | CAD | P27708 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL135321 | 1.00 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL6389383 | 1.00 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6389387 | 0.98 | ALOX15 (0.46) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL196141 | 0.98 | ALOX15 (0.46) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL135322 | 0.98 | ALOX15 (0.46) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3918851 | 0.95 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3918852 | 0.95 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL20267442 | 0.93 | ALOX15 (0.42) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL6846658 | 0.93 | ALOX15 (0.42) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL8848952 | 0.87 | ALOX15 (0.50) | ALOX15ALDH1A1LMNAHSD17B10MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3817814-B1 | CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-VALINE ETHYL ESTER | MERCK PATENT GMBH (DE) | 2023-09-20 | — | — | EP | claimed |
| CN-112876402-A | Synthetic method of 5F-EMB-PICA | 公安部物证鉴定中心 | 2021-06-01 | — | — | CN | claimed |
| EP-3082778-B1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2019-04-03 | — | — | EP | claimed |
| US-20160296475-A1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2016-10-13 | — | — | US | claimed |
| US-12516037-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-06 | — | — | US | disclosed |
| US-12509437-B2 | Substituted thiophene carboxamides and derivatives thereof as microbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-30 | — | — | US | disclosed |
| CN-115087650-B | Substituted thiophenecarboxamides and derivatives thereof as microbiocides | 拜耳公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240360098-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-10-31 | — | — | US | disclosed |
| CN-118580159-A | Synthesis method of nitrogen heterocyclic aromatic hydrocarbon modified beta-amino acid ester | 国科大杭州高等研究院 | 2024-09-03 | — | — | CN | disclosed |
| EP-4077303-B1 | SUBSTITUTED THIOPHENE CARBOXAMIDES AND DERIVATIVES THEREOF AS MICROBIOCIDES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| CN-114557401-B | Composite microbial feed and preparation method thereof | 云南大台农台标农业科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11952359-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-09 | — | — | US | disclosed |
| US-5189205-A | Reacting carbon dioxide with a primary amine to form an ammonium carbamate salt; reacting with an electrophilic or oxophilic salt | MONSANTO COMPAMY (US) | 1993-02-23 | — | — | US | disclosed |
| US-5112837-A | Inhibitors of thymidylate synthetase enzyme | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-12 | — | — | US | disclosed |
| US-4981856-A | QUINAZOLINE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-01 | — | — | US | disclosed |
| EP-0147211-B1 | 4H-3,1-BENZOXAZIN-4-ONES AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | SYNTEX (U.S.A.) INC. (US) | 1990-09-12 | — | — | EP | disclosed |
| EP-0318225-A2 | 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| EP-0284338-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509437-B2 | Substituted thiophene carboxamides and derivatives thereof as microbicides | CBR1, CBR3, CCR2 | GAA 3334/4885ALOX15 1931/4885SLC7A5 3036/4885 |
| US-20240360098-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | TST, TBK1, PGLS | GAA 279/4885ALOX15 3155/4885SLC7A5 1257/4885 |
| US-11952359-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | TST, XDH, PGLS | GAA 252/4885ALOX15 2228/4885SLC7A5 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.